Article History
Accepted: 7 September 2022
First Online: 10 October 2022
Competing interests
: J.D.I. has received research funding from GSK, Janssen and Pfizer, and speaker and/or consultancy fees from AbbVie, BMS, Gilead, Roche and UCB. F.A.H.C. has received speaker fees from AstraZeneca. A.L. declares no competing interests.